We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK) Rises But Trails Market: What Investors Should Know
Read MoreHide Full Article
In the latest trading session, GSK (GSK - Free Report) closed at $40.80, marking a +0.27% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.
Heading into today, shares of the drug developer had lost 6.16% over the past month, lagging the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8% in that time.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on May 1, 2024. In that report, analysts expect GSK to post earnings of $0.94 per share. This would mark year-over-year growth of 4.44%. Meanwhile, the latest consensus estimate predicts the revenue to be $8.99 billion, indicating a 6.47% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.03 per share and a revenue of $39.89 billion, indicating changes of +4.4% and +5.67%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for GSK. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, GSK is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, GSK is presently trading at a Forward P/E ratio of 10.1. This represents a discount compared to its industry's average Forward P/E of 23.42.
Investors should also note that GSK has a PEG ratio of 1.86 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.9 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Rises But Trails Market: What Investors Should Know
In the latest trading session, GSK (GSK - Free Report) closed at $40.80, marking a +0.27% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.
Heading into today, shares of the drug developer had lost 6.16% over the past month, lagging the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8% in that time.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on May 1, 2024. In that report, analysts expect GSK to post earnings of $0.94 per share. This would mark year-over-year growth of 4.44%. Meanwhile, the latest consensus estimate predicts the revenue to be $8.99 billion, indicating a 6.47% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.03 per share and a revenue of $39.89 billion, indicating changes of +4.4% and +5.67%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for GSK. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, GSK is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, GSK is presently trading at a Forward P/E ratio of 10.1. This represents a discount compared to its industry's average Forward P/E of 23.42.
Investors should also note that GSK has a PEG ratio of 1.86 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.9 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.